Equities analysts expect that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will post sales of $44.50 million for the current quarter, according to Zacks. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings. The highest sales estimate is $46.10 million and the lowest is $42.90 million. Eagle Pharmaceuticals posted sales of $56.05 million in the same quarter last year, which would indicate a negative year over year growth rate of 20.6%. The firm is expected to report its next earnings report on Thursday, February 27th.

According to Zacks, analysts expect that Eagle Pharmaceuticals will report full year sales of $192.35 million for the current year, with estimates ranging from $190.50 million to $194.20 million. For the next fiscal year, analysts anticipate that the firm will post sales of $204.20 million, with estimates ranging from $201.90 million to $206.50 million. Zacks’ sales averages are an average based on a survey of analysts that cover Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.17). Eagle Pharmaceuticals had a return on equity of 16.07% and a net margin of 12.72%. The company had revenue of $41.10 million for the quarter, compared to the consensus estimate of $45.44 million. During the same quarter in the previous year, the business earned $1.18 earnings per share. Eagle Pharmaceuticals’s revenue was down 19.9% compared to the same quarter last year.

Several equities analysts recently issued reports on EGRX shares. TheStreet lowered Eagle Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 22nd. ValuEngine lowered Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 6th. BidaskClub lowered Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, February 4th. Finally, Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, January 3rd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the stock. Eagle Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $60.25.

EGRX opened at $52.71 on Friday. The stock’s 50 day simple moving average is $57.68 and its 200 day simple moving average is $58.17. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.24 and a quick ratio of 4.07. Eagle Pharmaceuticals has a 1 year low of $40.66 and a 1 year high of $64.94. The firm has a market cap of $734.01 million, a price-to-earnings ratio of 28.11 and a beta of 1.59.

Hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. lifted its stake in shares of Eagle Pharmaceuticals by 233.8% in the 4th quarter. Meeder Asset Management Inc. now owns 741 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 519 shares during the period. LS Investment Advisors LLC lifted its stake in shares of Eagle Pharmaceuticals by 13.3% in the 4th quarter. LS Investment Advisors LLC now owns 2,255 shares of the specialty pharmaceutical company’s stock valued at $135,000 after purchasing an additional 265 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in shares of Eagle Pharmaceuticals in the 4th quarter valued at approximately $206,000. Wedge Capital Management L L P NC purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at approximately $268,000. Finally, Crossmark Global Holdings Inc. lifted its stake in shares of Eagle Pharmaceuticals by 5.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 4,748 shares of the specialty pharmaceutical company’s stock valued at $285,000 after purchasing an additional 230 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Featured Article: What is the accumulation/distribution indicator?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.